Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas

[21] Klotz L(1998)Familial study of prostate cancer in Jamaica Urology 69 1165-3271

[22] McGowan T(2012)Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica Cancer Causes Control 9 e107275-473

[23] Srigley J(2007)GSTM1 and GSTT1 polymorphisms and the risk of prostate cancer in a Caribbean population of African descent Urology 28 3457-358

[24] Evans A(2014)Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in the Caribbean population of African descent PLoS ONE 97 511-1109

[25] Curado MP(2010)Chlordecone exposure and risk of prostate cancer J Clin Oncol 93 S44-1156

[26] de Souza DLB(2016)Effect of long-term hormonal theapy (vs. short-term hormonal therapy): a secondary analysis of intermediate-risk prostate cancer patients treated on NRG Oncology RTOG 9202 Int J Radiat Oncol Phys. 229 3265-235

[27] Bray F(2016)Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology/RTOG 9202 Int J Radiat Oncol Phys 15 464-undefined

[28] Pineros M(2013)Long-term outcomes for men with high-risk prostate cancer treated definitively with external bean radiotherapy with or without androgen deprivation Cancer 23 347-undefined

[29] Mensah JE(2014)Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial Lancet Oncol 70 1102-undefined

[30] Yarney J(2016)Black Heterogeneity in Cancer Mortality: US-Blacks, Haitians and Jamaicans Cancer Control 25 1147-undefined

[21] Klotz L(1998)Familial study of prostate cancer in Jamaica Urology 69 1165-3271

[22] McGowan T(2012)Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica Cancer Causes Control 9 e107275-473

[23] Srigley J(2007)GSTM1 and GSTT1 polymorphisms and the risk of prostate cancer in a Caribbean population of African descent Urology 28 3457-358

[24] Evans A(2014)Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in the Caribbean population of African descent PLoS ONE 97 511-1109

[25] Curado MP(2010)Chlordecone exposure and risk of prostate cancer J Clin Oncol 93 S44-1156

[26] de Souza DLB(2016)Effect of long-term hormonal theapy (vs. short-term hormonal therapy): a secondary analysis of intermediate-risk prostate cancer patients treated on NRG Oncology RTOG 9202 Int J Radiat Oncol Phys. 229 3265-235

[27] Bray F(2016)Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology/RTOG 9202 Int J Radiat Oncol Phys 15 464-undefined

[28] Pineros M(2013)Long-term outcomes for men with high-risk prostate cancer treated definitively with external bean radiotherapy with or without androgen deprivation Cancer 23 347-undefined

[29] Mensah JE(2014)Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial Lancet Oncol 70 1102-undefined

[30] Yarney J(2016)Black Heterogeneity in Cancer Mortality: US-Blacks, Haitians and Jamaicans Cancer Control 25 1147-undefined